Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics has entered a collaboration with Danish biotech firm Biomia ApS to apply IRLAB’s Integrative Screening Process (ISP) platform to Biomia’s small-molecule drug candidates targeting undisclosed central nervous system indications. Under the agreement, IRLAB will use its ML/AI-supported ISP technology to provide phenotypic characterization, indication prediction, and differentiation versus existing treatments for Biomia’s novel chemistries, while Biomia supplies the compounds and funds the studies, reinforcing IRLAB’s position as a specialist CNS discovery partner and potentially expanding the commercial reach and validation of its ISP platform within the broader biotech ecosystem.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on discovering and developing transformative treatments for all stages of Parkinson’s disease and other central nervous system disorders. Originating from Nobel Laureate Arvid Carlsson’s research on neurotransmitter imbalances, the company’s pipeline includes Mesdopetam, which has completed Phase IIb and is being prepared for Phase III in levodopa-induced dyskinesias, Pirepemat in Phase IIb for reducing fall frequency in Parkinson’s patients, IRL757 in Phase I for apathy in neurodegenerative diseases, and two preclinical programs, IRL942 and IRL1117. Its drug candidates are generated through its proprietary systems biology-based discovery platform, the Integrative Screening Process (ISP), and the company is listed on Nasdaq Stockholm.
YTD Price Performance: 1.52%
Average Trading Volume: 192,168
Technical Sentiment Signal: Sell
Current Market Cap: SEK169.9M
Find detailed analytics on IRLAB.A stock on TipRanks’ Stock Analysis page.